Tratamiento de la artritis psoriásica con ustekinumab en diferentes escenarios clínicos
Casos reales y revisión de la literatura
Resumen
El tratamiento de la Artritis Psoriásica (APs) se basa en suprimir los signos y síntomas en todos los componentes de la enfermedad (articular, piel, entesis, compromiso axial). Dentro de las opciones terapéuticas contamos con los antinflamatorios no esteroideos (AI-NEs), corticoides, drogas modificadoras de la enfermedad (DMARs) entre ellas el metotrexato y leflunomida, y los anti-TNF. Estas úl-timas han demostrado actualmente amplia eficacia a largo plazo y buen perfil de seguridad. Fueron el único mecanismo de acción para el tratamiento de la APs; sin embargo en el último año fue aprobado en varios países, ustekinumab, un inhibidor de la subu-nidad p40 de la IL12 y 23. Esta revisión presenta una serie de 6 casos clínicos donde hemos utilizado esta opción terapéutica en diferentes escenarios.Citas
I. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14-17.
II. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic re-view of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.
III. Soriano ER, Javier Rosa, Edson Velozo, Schpilberg M, Imamura PM, Diaz J, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheu-matology (Oxford). 2011 Apr;50(4):729-34.
IV. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-864.
V. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large inter-national study. Arthritis Rheum. 2006;54(8):2665-2673.
VI. Gladman DD, Farewell VT, Wong K, Husted. Mortal-ity studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41(6):1103-10.
VII. Ficco H, Citera G, Maldonado Cocco JA. revalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Maldonado Clin Rheuma-tol. 2014 Feb;33(2):243-6.
VIII. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheuma-tism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2015;0:1–12.
IX. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta Felquer M, Armstrong AW, et al. Group for re-search and assessment of psoriasis and psoriatic arthri-tis: Treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 2016 Jan 8. doi: 10.1002/ art.39573. [Epub ahead of print].
X. S aad AA, Symmons DP, Noyce PR, Ashcroft DM. Risk and benefits of tumor necrosis factor alpha inhibi-tors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled tri-als. Journal Rheumatol. 2008;35(5):883-890.
XI. Soriano ER, Rosa J. Update on the treatment of pe-ripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep. 2009;11(4):270-277.
XII. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/ Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350.
XIII. Felquer ML, Soriano ER. New treatment paradigms in psoriatic arthritis: an update on new therapeutics ap-proved by the U.S. Food and Drug Administration. Curr Opin Rheumatol. 2015;27(2):99-106.
XIV. Davari P, Leo MS, Kamangar F, Fazel N. Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol. 2014;7:243-249.
XV. K ingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized place bo-controlled trial of methotrexate in psoriatic arthri-tis. Rheumatology (Oxford). 2012 Aug;51(8):1368-77.
XVI. Coates LC, Moverley AR, McParland L, Brown S, Na-varro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2489-98.
XVII. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guz-zo C, Wang Y, et al. Efficacy and safety of ustekinum-ab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
XVIII. P app KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-1684.
XIX. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
XX. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized,placebo-controlled trial in Taiwan-ese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-163.
XXI. M cInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthri-tis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789.
XXII. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug sur-vival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis fac-tor ± inhibitor therapy: results from the Danish Na-tionwide DANBIO Registry. Arthritis Rheum. 2013 May;65(5):1213-23.
XXIII. K ristensen L, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H, et al. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Co-hort Study from Southern Sweden. J Rheumatol. 2016 Jan;43(1):81-7.
XXIV. Fagerli KM1, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rødevand E, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013 Nov;72(11):1840-4. J Rheumatol 2016;43;81-87.
XXV. García Salinas R, Arturi P, Magri P, Girard Bosch MP, Arturi AS. Tocilizumab en artritis psoriásica ante la falla a los bloqueantes del factor de necrosis tumoral alfa: experiencia en dos casos. Rev Arg Reumatol. 2014;25(1): 24-28.
XXVI. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, mul-ticentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-999.
XXVII. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of clinical efficacy and radio-graphic benefit through two years of ustekinumab thera-py in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1739-49.
XXVIII. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Sza-pary PO, Wasfi Y, et al. Longterm safety of ustekinum-ab in patients with moderate-to-severe psoriasis: fi-nal results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844-854.
XXIX. Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of Serious Infection With Bio-logic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015 Sep;151(9):961-9.
XXX. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoria-sis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1371-7.
XXXI. Setty AR, Curhan G, Choi HK. Obesity, waist cir-cumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007 Aug 13-27;167(15):1670-5.
XXXII. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gel-fand JM, et al. Obesity and the risk of psoriatic arthri-tis: a population-based study. Ann Rheum Dis. 2012 Aug;71(8):1273-7.
XXXIII. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011 Apr;164(4):862-72.
XXXIV. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91.
Derechos de autor 2016 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
